Ensitrelvir is an oral SARS-CoV-2 main protease (Mpro/3CLpro) inhibitor indicated for post-exposure prophylaxis of COVID-19 in adults and adolescents 12 years of age and older following contact with an infected individual. Ensitrelvir is an oral small-molecule antiviral that inhibits the SARS-CoV-2 main protease (Mpro, also known as 3CLpro), an enzyme the virus needs to replicate.
- Mechanism
- Curator reviewed · 4 references
Ensitrelvir is a SARS-CoV-2 antiviral drug that acts as an inhibitor of the SARS-CoV-2 main protease (Mpro), also referred to as 3C-like protease (3CLpro) or nonstructural protein 5 (nsp5) protease. Ensitrelvir binds directly to the Mpro active site, as demonstrated by X-ray crystallography. By inhibiting Mpro, ensitrelvir renders the enzyme incapable of processing the viral polyproteins pp1a and pp1ab, which prevents viral replication. In a biochemical assay, ensitrelvir inhibited recombinant SARS-CoV-2 Mpro activity with an IC50 value of 13.2 nM.
- Primary indication
- Ensitrelvir is indicated for post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19.Curator reviewed · 1 structured indication
- Formula / weight
- C22H17ClF3N9O2 · 531.88 g/mol (avg)
- First approval
- United States, 2026
- Code names
- S-217622
- Brand names
Resolves to
QMPBBNUOBOFBFS-UHFFFAOYSA-NSMILESCN1C=NC(CN2C(=O)NC(=NC3=CC4=CN(C)N=C4C=C3Cl)N(CC3=CC(F)=C(F)C=C3F)C2=O)=N1What you can answer from here — as of September 26, 2026
Which drugs share a target with Ensitrelvir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account